Skip to main content
CBD's War On Big Tobacco
This new invention has the $930 billion tobacco industry shaking in its boots. Don't miss this coming trend.
Get The Full Story Before Wall Street

TCON Insider Trading (TRACON Pharmaceuticals)

Insider Ownership Percentage: 23.30%
Insider Buying (Last 12 Months): $11,343,025.79
Insider Selling (Last 12 Months): $0.00

TRACON Pharmaceuticals Insider Trading History Chart

TRACON Pharmaceuticals Share Price & Price History

$6.21
▼ -0.49 (-7.31%)
As of 05/6/2021 01:00 AM ET
Days: 30 | 90 | 365
This tech company just released their 2020 financial statements
You don't want to miss this
Read more about them here!

TRACON Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/8/2021Scott B. BrownCFOBuy1,000$8.30$8,300.00View SEC Filing Icon  
1/27/2021Charles TheuerCEOBuy11,000$8.98$98,780.00201,232View SEC Filing Icon  
12/30/2020Ikarian Capital, LlcMajor ShareholderBuy520,291$9.61$4,999,996.51View SEC Filing Icon  
12/29/2020Mark C. WigginsinsiderBuy1,000$10.57$10,570.00190,232View SEC Filing Icon  
12/22/2020Opaleye Management Inc.Major ShareholderBuy496,277$8.06$3,999,992.62View SEC Filing Icon  
10/21/2020Charles TheuerCEOBuy2,000$4.38$8,760.00View SEC Filing Icon  
10/21/2020Opaleye Management Inc.Major ShareholderBuy8,656$4.40$38,086.40View SEC Filing Icon  
9/23/2020Charles TheuerCEOBuy5,000$4.72$23,600.00186,775View SEC Filing Icon  
9/23/2020Opaleye Management Inc.Major ShareholderBuy57,200$4.83$276,276.00View SEC Filing Icon  
9/11/2020Ikarian Capital, LlcMajor ShareholderBuy78,201$3.93$307,329.93View SEC Filing Icon  
9/10/2020Mark C. WigginsInsiderBuy7,000$4.14$28,980.00View SEC Filing Icon  
9/9/2020Opaleye Management Inc.Major ShareholderBuy47,500$3.47$164,825.00View SEC Filing Icon  
9/4/2020Charles TheuerCEOBuy10,000$2.58$25,800.00176,882View SEC Filing Icon  
9/4/2020Opaleye Management Inc.Major ShareholderBuy9,058$2.88$26,087.04View SEC Filing Icon  
9/2/2020Opaleye Management Inc.Major ShareholderBuy119,800$2.35$281,530.00View SEC Filing Icon  
8/31/2020Opaleye Management Inc.Major ShareholderBuy302,150$1.76$531,784.00View SEC Filing Icon  
8/27/2020Opaleye Management Inc.Major ShareholderBuy183,354$1.71$313,535.34View SEC Filing Icon  
8/20/2020Charles TheuerCEOBuy30,000$1.58$47,400.00166,557View SEC Filing Icon  
8/18/2020Charles TheuerCEOBuy44,743$1.63$72,931.0991,814View SEC Filing Icon  
8/14/2020Charles TheuerCEOBuy100$1.70$170.0091,814View SEC Filing Icon  
8/12/2020Charles TheuerCEOBuy15,000$1.75$26,250.0076,714View SEC Filing Icon  
6/24/2020Charles TheuerCEOBuy9,895$1.90$18,800.5071,714View SEC Filing Icon  
6/15/2020Saundra L PelletierDirectorBuy3,000$2.07$6,210.002,500View SEC Filing Icon  
6/11/2020Saundra L PelletierDirectorBuy2,500$2.00$5,000.002,500View SEC Filing Icon  
5/22/2020Charles TheuerCEOBuy10,592$2.08$22,031.36View SEC Filing Icon  
3/12/2020Charles TheuerCEOBuy10,000$1.18$11,800.0031,777View SEC Filing Icon  
3/10/2020Charles TheuerCEOBuy10,000$1.87$18,700.0026,777View SEC Filing Icon  
1/23/2020Mark C WigginsInsiderBuy5,000$4.02$20,100.005,000View SEC Filing Icon  
8/9/2019Charles TheuerInsiderBuy50,000$0.45$22,500.00173,565View SEC Filing Icon  
12/21/2018Charles TheuerCEOBuy49,000$0.66$32,340.00View SEC Filing Icon  
11/29/2018Cross-Border Opportu PuissanceMajor ShareholderBuy4,326$1.13$4,888.38View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for TRACON Pharmaceuticals (NASDAQ:TCON)

42.03% of TRACON Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

TRACON Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/5/2021Total Clarity Wealth Management Inc.6,825$56K0.0%N/A0.044%Search for SEC Filing on Google Icon
4/29/2021We Are One Seven LLC11,780$96K0.0%-26.4%0.076%Search for SEC Filing on Google Icon
4/29/2021Dowling & Yahnke LLC40,455$0.33M0.0%+32.8%0.261%Search for SEC Filing on Google Icon
4/28/2021Lindbrook Capital LLC6,500$53K0.0%N/A0.042%Search for SEC Filing on Google Icon
2/17/2021Jane Street Group LLC11,041$0.13M0.0%-71.5%0.081%Search for SEC Filing on Google Icon
2/16/2021Price T Rowe Associates Inc. MD13,900$0.16M0.0%N/A0.102%Search for SEC Filing on Google Icon
2/12/2021Opaleye Management Inc.2,518,371$29.47M3.8%+25.1%18.402%Search for SEC Filing on Google Icon
2/12/2021Ikarian Capital LLC2,716,840$31.79M1.4%+25.6%19.853%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC169,100$1.98M0.0%+107.5%1.236%Search for SEC Filing on Google Icon
2/9/2021Wells Fargo & Company MN7,329$86K0.0%+166.1%0.054%Search for SEC Filing on Google Icon
2/9/2021Bank of New York Mellon Corp62,421$0.73M0.0%N/A0.456%Search for SEC Filing on Google Icon
2/5/2021BlackRock Inc.325,970$3.81M0.0%+5,758.6%2.382%Search for SEC Filing on Google Icon
2/4/2021GSA Capital Partners LLP46,375$0.54M0.1%-43.2%0.339%Search for SEC Filing on Google Icon
1/14/2021Vigilare Wealth Management14,000$0.16M0.2%-17.6%0.102%Search for SEC Filing on Google Icon
12/11/2020Virtu Financial LLC61,180$0.32M0.1%+58.3%0.447%Search for SEC Filing on Google Icon
11/17/2020Jane Street Group LLC38,749$0.20M0.0%N/A0.283%Search for SEC Filing on Google Icon
11/16/2020Boothbay Fund Management LLC236,301$1.22M0.1%N/A1.727%Search for SEC Filing on Google Icon
11/6/2020GSA Capital Partners LLP81,675$0.42M0.1%N/A0.597%Search for SEC Filing on Google Icon
11/3/2020Lindbrook Capital LLC10,000$52K0.0%N/A0.085%Search for SEC Filing on Google Icon
10/30/2020We Are One Seven LLC16,000$83K0.0%N/A0.137%Search for SEC Filing on Google Icon
10/19/2020Dowling & Yahnke LLC30,455$0.16M0.0%+48.9%0.260%Search for SEC Filing on Google Icon
10/15/2020Vigilare Wealth Management17,000$88K0.1%N/A0.145%Search for SEC Filing on Google Icon
9/15/2020Two Sigma Advisers LP55,400$0.11M0.0%+326.2%0.473%Search for SEC Filing on Google Icon
8/14/2020Telemetry Investments L.L.C.125,401$0.25M0.7%+88.9%2.280%Search for SEC Filing on Google Icon
8/7/2020Virtu Financial LLC38,650$76K0.0%N/A0.703%Search for SEC Filing on Google Icon
7/16/2020Wedbush Securities Inc.25,704$50K0.0%N/A0.467%Search for SEC Filing on Google Icon
5/15/2020Dowling & Yahnke LLC15,000$26K0.0%N/A0.273%Search for SEC Filing on Google Icon
5/15/2020Two Sigma Investments LP35,686$61K0.0%N/A0.649%Search for SEC Filing on Google Icon
5/12/2020JPMorgan Chase & Co.34,080$57K0.0%N/A0.620%Search for SEC Filing on Google Icon
2/14/2020Puissance Capital Management LP76,048$0.18M0.4%-98.3%2.423%Search for SEC Filing on Google Icon
2/13/2020Renaissance Technologies LLC151,529$0.36M0.0%-88.2%4.827%Search for SEC Filing on Google Icon
1/24/2020NEA Management Company LLC346,718$0.81M0.0%-90.0%11.042%Search for SEC Filing on Google Icon
10/17/2019Wedbush Securities Inc.146,000$65K0.0%+207.4%0.488%Search for SEC Filing on Google Icon
8/16/2019Susquehanna International Group LLP38,323$26K0.0%N/A0.128%Search for SEC Filing on Google Icon
8/14/2019Vanguard Group Inc.879,885$0.60M0.0%-19.0%2.939%Search for SEC Filing on Google Icon
8/13/2019BlackRock Inc.55,056$38K0.0%-46.0%0.184%Search for SEC Filing on Google Icon
8/12/2019Renaissance Technologies LLC1,209,203$0.82M0.0%+17.5%4.039%Search for SEC Filing on Google Icon
8/1/2019Wedbush Securities Inc.47,500$32K0.0%N/A0.159%Search for SEC Filing on Google Icon
5/10/2019Nicolet Advisory Services LLC35,701$49K0.0%N/A0.119%Search for SEC Filing on Google Icon
2/14/2019Telemetry Investments L.L.C.966,975$0.61M0.4%+153.5%3.237%Search for SEC Filing on Google Icon
11/13/2018Renaissance Technologies LLC808,100$1.66M0.0%+12.3%2.705%Search for SEC Filing on Google Icon
11/13/2018Bridgeway Capital Management Inc.100,000$0.21M0.0%+100.0%0.335%Search for SEC Filing on Google Icon
9/17/2018683 Capital Management LLC2,738,938$7.07M0.5%+82.6%9.179%Search for SEC Filing on Google Icon
8/13/2018Renaissance Technologies LLC719,900$1.94M0.0%+40.7%4.056%Search for SEC Filing on Google Icon
8/10/2018Dimensional Fund Advisors LP76,999$0.21M0.0%+368.8%0.434%Search for SEC Filing on Google Icon
5/11/2018X Square Capital LLC79,198$0.18M0.2%-39.2%0.446%Search for SEC Filing on Google Icon
5/10/2018NEA Management Company LLC3,467,181$7.98M0.4%+25.7%19.533%Search for SEC Filing on Google Icon
5/8/2018Alambic Investment Management L.P.92,611$0.21M0.0%N/A0.522%Search for SEC Filing on Google Icon
2/15/2018683 Capital Management LLC1,490,000$4.99M0.4%+49.7%8.509%Search for SEC Filing on Google Icon
2/14/2018QVT Financial LP124,966$0.40M0.0%-59.5%0.714%Search for SEC Filing on Google Icon
2/13/2018Renaissance Technologies LLC264,700$0.89M0.0%+73.0%1.512%Search for SEC Filing on Google Icon
2/12/2018X Square Capital LLC130,204$0.44M0.5%N/A0.744%Search for SEC Filing on Google Icon
12/7/2017683 Capital Management LLC995,000$3.13M0.3%N/A5.682%Search for SEC Filing on Google Icon
11/3/2017Candriam Luxembourg S.C.A.143,000$0.45M0.0%N/A0.861%Search for SEC Filing on Google Icon
8/10/2017Franklin Resources Inc.453,264$1.09M0.0%-47.9%2.729%Search for SEC Filing on Google Icon
7/26/2017NEA Management Company LLC2,759,217$6.62M0.2%No Change16.613%Search for SEC Filing on Google Icon
5/15/2017Eventide Asset Management LLC900,000$3.38M0.2%+4.0%5.568%Search for SEC Filing on Google Icon
5/12/2017Renaissance Technologies LLC63,200$0.24M0.0%+56.8%0.391%Search for SEC Filing on Google Icon
5/10/2017NEA Management Company LLC2,759,217$10.35M0.4%No Change17.071%Search for SEC Filing on Google Icon
5/10/2017Stifel Financial Corp30,200$0.11M0.0%+1.5%0.187%Search for SEC Filing on Google Icon
4/21/2017Candriam Luxembourg S.C.A.143,000$0.54M0.0%No Change0.885%Search for SEC Filing on Google Icon
2/14/2017Perceptive Advisors LLC100,000$0.49M0.0%N/A0.765%Search for SEC Filing on Google Icon
2/14/2017Eventide Asset Management LLC865,526$4.24M0.3%+67.2%6.625%Search for SEC Filing on Google Icon
2/14/2017Alyeska Investment Group L.P.100,000$0.49M0.0%N/A0.765%Search for SEC Filing on Google Icon
2/14/2017Franklin Resources Inc.869,565$4.26M0.0%N/A6.656%Search for SEC Filing on Google Icon
2/13/2017Renaissance Technologies LLC40,300$0.20M0.0%+181.8%0.308%Search for SEC Filing on Google Icon
2/13/2017Sii Investments Inc. WI29,406$0.14M0.0%-17.6%0.225%Search for SEC Filing on Google Icon
1/18/2017Wall Street Associates241,536$1.18M0.8%No Change1.849%Search for SEC Filing on Google Icon
11/10/2016NEA Management Company LLC1,889,652$12.60M0.6%No Change15.485%Search for SEC Filing on Google Icon
8/15/2016Deerfield Management Co.67,567$0.30M0.0%-83.0%0.554%Search for SEC Filing on Google Icon
7/28/2016ClariVest Asset Management LLC56,500$0.25M0.0%+56.9%0.463%Search for SEC Filing on Google Icon
7/26/2016Candriam Luxembourg S.C.A.143,000$0.63M0.0%-12.3%1.172%Search for SEC Filing on Google Icon
5/16/2016Deerfield Management Co.397,085$2.78M0.1%-18.1%3.259%Search for SEC Filing on Google Icon
5/13/2016Geode Capital Management LLC24,420$0.17M0.0%-0.2%0.200%Search for SEC Filing on Google Icon
2/12/2016Visium Asset Management LP436,336$4.03M0.1%No Change3.584%Search for SEC Filing on Google Icon
1/26/2016Candriam Luxembourg S.C.A.180,000$1.66M0.0%+33.0%1.478%Search for SEC Filing on Google Icon
1/24/2016NEA Management Company LLC1,889,652$17.46M1.1%No Change0.000%Search for SEC Filing on Google Icon
9/30/2015J. Goldman & Company170,000$1.66M0.1%N/A1.396%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
TRACON Pharmaceuticals logo
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Read More on TRACON Pharmaceuticals

Today's Range

Now: $6.21
$5.84
$6.70

50 Day Range

MA: $8.15
$6.70
$9.65

52 Week Range

Now: $6.21
$1.55
$12.20

Volume

212,238 shs

Average Volume

398,033 shs

Market Capitalization

$96.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02

Who are the company insiders with the largest holdings of TRACON Pharmaceuticals?

TRACON Pharmaceuticals' top insider shareholders include:
  1. Charles Theuer (CEO)
  2. Mark C Wiggins (Insider)
  3. Charles Theuer (Insider)
  4. Mark C Wiggins (Insider)
  5. Saundra L Pelletier (Director)
  6. Ikarian Capital, Llc (Major Shareholder)
  7. Opaleye Management Inc (Major Shareholder)
  8. Scott B Brown (CFO)

Who are the major institutional investors of TRACON Pharmaceuticals?

TRACON Pharmaceuticals' top institutional shareholders include:
  1. Dowling & Yahnke LLC — 0.26%
  2. We Are One Seven LLC — 0.08%
  3. Total Clarity Wealth Management Inc. — 0.04%
  4. Lindbrook Capital LLC — 0.04%

Which institutional investors are selling TRACON Pharmaceuticals stock?

In the previous quarter, TCON stock was sold by these institutional investors:
  1. We Are One Seven LLC

Which institutional investors are buying TRACON Pharmaceuticals stock?

Within the last quarter, TCON stock was purchased by institutional investors including:
  1. Dowling & Yahnke LLC
  2. Total Clarity Wealth Management Inc.
  3. Lindbrook Capital LLC
In the last year, these company insiders have bought TRACON Pharmaceuticals stock:
  1. Charles Theuer (CEO)
  2. Mark C Wiggins (Insider)
  3. Charles Theuer (Insider)
  4. Mark C Wiggins (Insider)
  5. Saundra L Pelletier (Director)
  6. Ikarian Capital, Llc (Major Shareholder)
  7. Opaleye Management Inc (Major Shareholder)
  8. Scott B Brown (CFO)
CBD Upstart Wages War On The $930 Billion Tobacco Giants
This company has created a new "CBD Cigarette" that has Big Tobacco scared. Their invention could steal market share from tobacco very quickly.
Click Here To Get The Full Story Now!